TERT mutations exhibited a survival advantage over other early mutations, such as CDKN2A/B and PTEN. More importantly, through high-level mathematical estimates, the authors were able to propose that an IDH wild-type GBM may grow for 2–7 years undetected [53]. The gene discussed is CDKN2A; the disease is glioblastoma.